Ten Healthcare Companies Secure Funding This Week, Two Raise Over RMB 100 Million Each
Genocury
Developer of Novel Therapies in Oncology Genetics and Cell Therapy
Healinno Tech
Developer and Manufacturer of Surgical Robots and Intelligent Diagnostic and Therapeutic Equipment
According to incomplete statistics from the People's Daily Health Client, a total of 10 companies in China's pharmaceuticals and health sector received financing this week (May 13 to May 17). The financed companies are involved in fields such as tumor drug research and development, precision pathogen diagnosis, surgical robots, and mass spectrometry equipment R&D.
Biopharmaceuticals
Shenzhen Xiling Biopharmaceutical Technology Co., Ltd. Completes Pre-A Round Financing of Tens of Millions, Committed to Malignant Tumor Treatment
On May 17, Shenzhen Xiling Biopharmaceutical Technology Co., Ltd. received tens of millions of yuan in Pre-A round funding from Horse Racing Capital. The funds will be used to develop innovative tumor treatment technologies, involving research on natural killer cells (NK cells), gene therapy, and other fields, aiming to create breakthrough new therapies.
Shenzhen Xiling Biopharmaceutical Technology Co., Ltd. is a high-growth project independently incubated in the Kaido Biotechnology Innovation Park, focusing on fundamental oncology research and the development of advanced therapeutic technologies.
Jiyin Biotech Completes Tens of Millions of Angel+ Round Financing to Drive In Vivo CAR-T Therapy Development
On May 15, JiYin Biotechnology completed an angel+ round of financing worth tens of millions of yuan, exclusively invested by Tianchuang Capital. This round of financing will mainly be used for the optimization and upgrading of the core technology platform and the advancement of the in vivo CAR-T pipeline to the clinical stage.
Jiyin Bio is an innovative company dedicated to providing affordable universal cell therapy drugs for cancer patients. Its in vivo CAR-T therapeutic drug has completed preclinical development and is actively advancing investigator-initiated clinical trials (IIT).
Medical Device
Aikai Medical Completes Tens of Millions in Financing for Mass Production of Digital Neuroelectric Stimulation Therapy Devices
On May 16, Aikai Medical reached a multi-million-level investment agreement with the Management Committee of Shandong Juxian Economic Development Zone for a computing power center and precision electronic medical device project. This round of investment will mainly be used for the mass production of Aikai Medical's digital neuroelectrical stimulation therapy devices, including new product development, clinical research, registration applications, core technology iteration, and commercial expansion.
Aikai Medical, established in 2018, is a company specializing in digital diagnosis and treatment, medical big data applications, as well as comprehensive hospital-wide and regional healthcare IT solutions.
Dalian Elite Analytical Instruments Co., Ltd. Secures RMB 100 Million in A+ Round Financing for Product Line Structural Upgrade
On May 15, Dalian Elite Analytical Instruments Co., Ltd. announced the completion of its A+ round of financing worth hundreds of millions of yuan. This round of financing was jointly led by Junxin Capital and Guotai Junan Innovative Investment, with Yimei Investment participating. The funds will continue to be used for new product development, overseas channel expansion, and daily operations.
Dalian Elite Analytical Instruments Co., Ltd. is a liquid chromatography enterprise with independent research and development capabilities and the ability to achieve mass production of products. It leads in the market share of HPLC (High-Performance Liquid Chromatography) produced in China. The company has secured intellectual property rights for core liquid chromatography components through the strategic layout of over a hundred core patents.
PURSPEC Technologies Co., Ltd. Completes Nearly 100 Million Yuan in A+ Round Financing to Build a Miniaturized Mass Spectrometry Technology R&D Platform
On May 15, PURSPEC Technologies Co., Ltd. completed a nearly RMB 100 million A+ round of financing. This round of financing was exclusively invested by Tsinghua Holdings Jinxin, with Zhiyin Capital serving as the financial advisor for this round of financing. The funds raised will be used for product development, registration, and overseas sales.
PURSPEC Technologies Co., Ltd. specializes in the research, development, production, and service of high-end mass spectrometry detection equipment, providing real-time, accurate, and convenient detection solutions for on-site testing and scientific research.
Zhiyu Medical Completes Over 60 Million Yuan Pre-A++ Financing Round for Water Jet Robot Clinical Trials
On May 14, Zhiyu Healthcare completed a Pre-A++ round of financing exceeding 60 million yuan. This round of financing was led by CD Capital, with Legend Star following up. The funds raised will be used for clinical trials of the core product, a high-energy water jet autonomous surgical robot (water jet surgical robot), as well as the research and development layout of new product pipelines.
Zhiyu Medical focuses on the research and development of surgical robots and intelligent diagnosis and treatment equipment. Its main R&D directions include leading innovative products in the fields of minimally invasive urological surgery, interventional surgery, and natural orifice surgery.
Zhongjing Weishi Secures Tens of Millions in Pre-A Round Financing to Develop Innovative Eye Health Products
On May 14, ZJ Vision announced the completion of a multi-million yuan Pre-A round of financing, led by Ruihua Capital, with participation from Taiyu Investment and Fengqiao Capital. Goroad Capital served as the exclusive financial advisor. This round of financing will help ZJ Vision to continuously promote clinical research, marketing, brand building, and new technology development, as well as to develop more innovative eye health products.
Medical Services
Beijing Daytime Healthcare Completes Angel Round Financing, Committed to the Development and Research of the Daytime Healthcare Industry
On May 17, Beijing Daytime Medical completed its angel round of financing. This round of financing was exclusively invested by state-owned capital. The funds raised will be mainly used for the research and development of a new generation of daytime medical process and quality control management products, as well as the R&D and project delivery work of the rehabilitation service platform.
Beijing Daytime Medical mainly provides medical institutions with consulting services for the development planning of daytime medical models, construction plans for daytime surgery centers, and information-based solutions for full-process management and quality control. At the same time, it offers patients preoperative preparation and postoperative rehabilitation services, including accommodation, nursing, nutrition, psychological intervention, and science popularization education.
Microfar Genomics Completes Hundreds of Millions of D+ Round Financing, Focusing on Precise Pathogen Diagnosis
On May 16, Vision Medical announced the completion of a D+ round of financing worth hundreds of millions of RMB, led by Kequan Fund and participated by Tianxin Fund. The proceeds from this round of financing will mainly be used to promote the research and development and IVD transformation of pathogen molecular precision diagnostic products, and accelerate the implementation of comprehensive solutions in top-tier medical institutions across China. Meanwhile, Vision Medical will build a new production base for molecular diagnostic reagents and instruments.
Vision Medicals focuses on gene diagnosis and precision medicine for infectious diseases, striving to build an intelligent diagnostic system for infectious diseases based on genomics, radiomics, and the open-source big data platform E-MapReduce (EMR big data), providing comprehensive solutions for precise clinical diagnosis of infections.
ICE Bioscience Completes B++ Round Financing, Focusing on Novel Drug Targets and Drug Discovery
On May 14, ICE Bioscience announced the completion of its B++ round of financing. This round was led by Yizhuang Guotou, with existing shareholder Yahui Investment continuing to increase its shares. The funds raised will support ICE Bioscience in providing more advanced and higher quality services to pharmaceutical companies both in China and overseas.
ICE Bioscience Focuses on New Targets, Methods, and Technologies in Drug Discovery, Establishing an Integrated Platform for Target-Driven Drug Discovery Biology.
Change of Leadership, Medical Device Giant's Stock Price Rises in Response!
2024 Galien International Awards Nominations Announced! The 9 Most Innovative Medical Devices Globally
The First in China! Another Innovative Product Approved! (附全球创新获批盘点)
